🇺🇸 FDA
Pipeline program

Placebo for cemdisiran is 0.9% saline and will be supplied by the sponsor., Pozelimab, Placebo for pozelimab will be provided in an aqueous buffered solution and supplied by the sponsor., Cemdisiran

R3918-AMD-2326

Phase 3 small_molecule active

Quick answer

Placebo for cemdisiran is 0.9% saline and will be supplied by the sponsor., Pozelimab, Placebo for pozelimab will be provided in an aqueous buffered solution and supplied by the sponsor., Cemdisiran for Geographic Atrophy Secondary to Age-Related Macular Degeneration is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Geographic Atrophy Secondary to Age-Related Macular Degeneration
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials